Find disease awareness content and relevant supporting materials
The asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS): opportunities and challenges.
Purpose of review: Some individuals share characteristics of asthma and chronic obstructive pulmonary disease (COPD). The asthma-COPD overlap syndrome (ACOS) has been defined as symptoms of increased variability of airflow in association with an incompletely reversible airflow obstruction.
Indacaterol/glycopyrronium: a dual bronchodilator for COPD.
Indacaterol/glycopyrronium (IND/GLY) 110/50mcg was the first once-daily, long-acting β2-agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combination (FDC) approved in Europe for the treatment of chronic obstructive pulmonary disease (COPD).
Chronic obstructive pulmonary disease is not a risk factor for polyneuropathy: A prospective controlled study.
Polyneuropathy has been observed in patients with chronic obstructive pulmonary disease (COPD). If polyneuropathy occurs as a complication or extrapulmonary manifestation of COPD, one would expect an increased prevalence among patients with a cryptogenic axonal polyneuropathy.
Multi-target natural products as alternatives against oxidative stress in Chronic Obstructive Pulmonary Disease (COPD).
Historically, natural products (NPs) are the main source of potential drugs and their antioxidant potential has been widely recognized. Furthermore, various reports have suggested that NPs act as modulators of targets related to COPD...
Role of dual bronchodilators in COPD: A review of the current evidence for indacaterol/glycopyrronium.
In this review, we summarize the rationale for combining long-acting bronchodilators in the management of chronic obstructive pulmonary disease (COPD), and the evidence for the long-acting bronchodilator combination ...
New developments in optimizing bronchodilator treatment of COPD: a focus on glycopyrrolate/formoterol combination formulated by co-suspension delivery technology.
COPD causes considerable health and economic burden worldwide, with incidence of the disease expected to continue to rise. Inhaled bronchodilators, such as long-acting muscarinic antagonists (LAMAs) and long-acting β2-agonists (LABAs), are central to the maintenance treatment of patients with COPD.
Umeclidinium in chronic obstructive pulmonary disease: latest evidence and place in therapy.
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity, mortality and health care expenditure throughout the world. COPD guidelines recommend the use of long-acting muscarinic antagonist ...